Keywords: disappointment, genentech/actelion, veletri, trial, misses, target, actelion
Disappointment for Genentech/Actelion as Veletri trial misses target
Article | 23 April 2001
Actelion and Genentech's dual endothelin receptor antagonist Veletri(tezosentan) has achieved disappointing results in the RITZ-1 trial, involving patients with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
